Related Experiment Videos
Burkitt's and Burkitt-like lymphoma
1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine Medical School and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA.
Current Treatment Options in Oncology
|June 21, 2002
Summary
Aggressive Burkitt
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Burkitt's and Burkitt-like lymphoma (BL/BLL) are aggressive B-cell malignancies requiring prompt treatment.
- High proliferative rates can lead to rapid disease progression and fatal outcomes.
- Supportive care is crucial to manage complications like tumor lysis syndrome and renal failure.
Purpose of the Study:
- To review current understanding and therapeutic strategies for BL/BLL.
- To highlight advancements in chemotherapy and supportive care.
- To identify areas for future research in targeted therapies and molecular biology.
Main Methods:
- Review of clinical trials and treatment outcomes for BL/BLL.
- Analysis of survival rates in different age groups and HIV-associated cases.
- Discussion of emerging therapeutic approaches, including bone marrow transplantation and monoclonal antibodies.
Main Results:
- Dose-intensive chemotherapy with CNS prophylaxis yields 70-80% survival in young patients, but only 15-25% in older adults.
- Outcomes for HIV-associated BL/BLL have improved with better chemotherapy and HIV care.
- Autologous bone marrow transplantation is a feasible curative option for select patients.
Conclusions:
- BL/BLL remains a challenging but treatable aggressive lymphoma.
- Further research into molecular targets, like c-myc dysregulation, is needed for improved prognostication and targeted therapies.
- Integration of novel agents and continued clinical trials are essential to enhance cure rates.